

1 **Common and distinct patterns of task-related neural activation abnormalities in**
2 **patients with remitted and current major depressive disorder: A systematic**
3 **review and coordinate-based meta-analysis**

4 Zuxing Wang^{1*}, Peijia Wang¹, Danmei He^{2,3,4}, Lin Yang^{2,3,4}, Hongru Zhu^{2,3,4*}

5
6 1. Sichuan Provincial Center for Mental Health, The Center of Psychosomatic Medicine of Sichuan
7 Provincial People's Hospital, University of Electronic Science and Technology of China,
8 Chengdu, P. R. China.

9 2. Mental Health Center and psychiatric Laboratory, West China Hospital of Sichuan University,
10 Chengdu 610041, China.

11 3. Huaxi Brain Research Center, West China Hospital of Sichuan University, Chengdu 610041,
12 Sichuan, China.

13 4. Med-X Center for Informatics, Sichuan University, Chengdu 610041, Sichuan, China.

14
15 *Correspondence: Zuxing Wang (zuxingwang7090@163.com) at Sichuan Provincial Center for
16 Mental Health, The Center of Psychosomatic Medicine of Sichuan Provincial People's Hospital,
17 University of Electronic Science and Technology of China, Chengdu, P. R. China and Hongru Zhu
18 (zhuhongru@wchscu.cn) at Mental Health Center and psychiatric Laboratory, West China Hospital
19 of Sichuan University, Chengdu 610041, China.

20
21 **AUTHOR CONTRIBUTIONS**

22 Study conception and design: WZX, XJ, MWJ, HY, ZZL and ZHR. Data extraction and analyses:
23 WZX, WPJ, HDM, and YL. Paper drafted by WZX with input from WPJ, HDM, YL and ZHR. All
24 authors have seen and approved the manuscript.

25
26 **COMPETING INTERESTS**

27 The authors declare no competing interests.

28
29 **ACKNOWLEDGEMENTS**

30 This study was financially supported by the National Science Foundation of China (Grant No.
31 82171513); Institutional Research Fund from Sichuan University (No. 2022SCUH0026); Med-X
32 Center for Informatics funding project (No. YGJC012); 1-3-5 project for disciplines of excellence,
33 West China Hospital, Sichuan University (No. ZYJC21069) to Dr. H.Z.

34
35 **Short title: Major Depressive Disorder & Task-Related Neural Activation**

36 **Number of words in the abstract: 170**

37 **Number of words in the text: 4147**

38 **Number of tables: 3**

39 **Number of figure: 1**

40 **Number of supplementary tables: 3**

41 **Number of supplementary figures: 2**

1

2 **Abstract**

3 Whether remitted major depressive disorder (rMDD) and MDD present common or distinct
4 neuropathological mechanisms remains unclear. We performed a meta-analysis of task-related
5 whole-brain functional magnetic resonance imaging (fMRI) using anisotropic effect-size signed
6 differential mapping software to compare brain activation between rMDD/MDD patients and
7 healthy controls (HCs). We included 18 rMDD studies (458 patients and 476 HCs) and 120 MDD
8 studies (3746 patients and 3863 HCs). The results showed that MDD and rMDD patients shared
9 increased neural activation in the right temporal pole and right superior temporal gyrus. Several
10 brain regions, including the right middle temporal gyrus, left inferior parietal, prefrontal cortex, left
11 superior frontal gyrus and striatum, differed significantly between MDD and rMDD.
12 Meta-regression analyses revealed that the percentage of females with MDD was positively
13 associated with brain activity in the right lenticular nucleus/putamen. Our meta-analysis provides
14 useful insights for understanding the potential neuropathology of brain dysfunction in MDD,
15 developing more targeted and efficacious treatment and intervention strategies, and more
16 importantly, providing potential neuroimaging targets for early screening of MDD.

17 **Keywords:** major depressive disorder, remitted major depressive disorder, task-related, functional
18 magnetic resonance imaging, coordinate-based meta-analysis, distinct patterns, common patterns

19

20

21

22

23

1

2 **1. Introduction**

3 Major depressive disorder (MDD) is a debilitating and common mental disorder that results in
4 considerable social and individual impairment and a substantial burden of the disease overall (Malhi
5 et al., 2020). MDD is a highly recurrent disease with more people undergoing frequent episodes
6 than single episodes (Huang et al., 2019). In recent years, although numerous studies have
7 attempted to pursue more effective approaches for the diagnosis and treatment of MDD, the
8 underlying pathophysiological mechanism remains unclear.

9 Thanks to better public understanding of MDD and improvements in medical technology, many
10 people suffering from MDD have been able to find complete relief through systematic treatment
11 (Smoski et al., 2013; Wang et al., 2022). Although patients with MDD have shown improvement
12 according to a clinical symptom evaluation, individuals with remitted MDD (rMDD) still
13 demonstrate differences in cognitive function, neuroimaging, and metabolism when compared to
14 healthy controls (HCs) (Moriarty et al., 2022; van Kleef et al., 2022). These comparisons may assist
15 in identifying patients at risk for relapse and improving preventive treatment.

16 Over the past 30 years, functional magnetic resonance imaging (fMRI) studies have significantly
17 increased our understanding of the neural mechanisms underlying MDD by measuring functional
18 brain activity in MDD patients (Keren et al., 2018; Wang et al., 2015). However, the main problem
19 across experiments of task-fMRI studies in MDD is that the results cannot be replicated to a large
20 extent (Lemke et al., 2022; Li et al., 2022; Trettin et al., 2022). To date, heterogeneity, small sample
21 sizes and differences in analytical methods (e.g., region-of-interest (ROI) or whole-brain analyses)
22 have resulted in inconsistency in data collection and analysis. Previous meta-analyses of MDD and
23 rMDD found many neural activation changes, such as changes in the superior temporal gyrus (STG),

1 prefrontal cortex, insula, striatum, middle temporal gyrus (MTG), superior frontal gyrus and limbic
2 system (Gong et al., 2020; Palmer et al., 2014; Wang et al., 2022). However, it is unclear whether
3 alterations in neural activation can differentiate MDD from rMDD or whether common
4 abnormalities are present in MDD patients in both the current and remitted states. Only a few
5 studies have focused on the comparison of functional neuroimages between rMDD and MDD
6 patients (Ming et al., 2017; Yang et al., 2018). Several meta-analyses have been carried out to
7 analyze the common and distinct patterns of neural activation during various tasks in patients with
8 different mental disorders (Gong et al., 2020; Janiri et al., 2020). However, to the best of our
9 knowledge, no meta-analyses have examined the use of fMRI in assessing common and distinct
10 patterns in brain activity during different tasks between rMDD and MDD patients.

11 An important question in fMRI studies of MDD patients is whether the abnormally activated
12 brain areas are acquired alterations or inherent to MDD, which is particularly related to the study of
13 the functional neuroanatomical circuits underlying MDD, as growing evidence indicates that the
14 final MDD pathology results from both susceptible and acquired neural alterations (Kambeitz et al.,
15 2017; Thalamuthu et al., 2022). In particular, when exploring between-group alterations in neural
16 activation in MDD patients compared to HCs, it is often unclear whether such functional
17 abnormalities correspond to preexisting vulnerabilities or secondary deficits specific to MDD onset.
18 Acquired deficits may be further separated due to disease-specific neurological abnormalities and
19 brain function changes after MDD remission. The above distinctions may be teased apart by
20 comparing patients with MDD to HCs, rMDD patients to HCs, rMDD patients to MDD patients,
21 and overlap analyses.

22 This study sought to use a voxel-based meta-analysis to examine brain activation alterations in
23 patients with rMDD and MDD, using data from a large number of task-related studies.

1 Meta-regressions were performed to explore how age, sex, duration of illness, number of episodes,
2 and severity of depressive symptoms might affect task-related brain activation (Spets and Slotnick,
3 2021; Yu et al., 2019). Our study not only enables a more precise understanding of the
4 pathophysiological mechanism of MDD but also contributes to the identification of potential
5 biomarkers for prevention and intervention of MDD.

6 **2. Methods**

7 **2.1 Literature Search and Article Inclusion**

8 A comprehensive literature review was performed in the EMBASE, PubMed and Web of Science
9 databases for task-related neuroimaging researches of MDD and rMDD patients published from
10 June 1999 through May 2022. Furthermore, we scoured review articles and references sections of
11 all retrieved studies for additional information. Literature search, study evaluation, and selection
12 were independently performed by two researchers using the following keywords: ‘remitted’,
13 ‘remission’, ‘euthymic’, ‘recovered’, ‘MDD’, ‘unipolar depression’, ‘depressive disorder’, ‘major
14 depressive disorder’, ‘fMRI’, ‘functional magnetic resonance imaging’, and ‘neuroimaging’. The
15 search formulas for above databases are available in the Supplementary Materials. Any
16 discrepancies were resolved by the addition of a third investigator to make a final decision. This
17 study is registered with PROSPERO (registration number CRD42022365170) and we followed the
18 Preferred Reporting Items for Systematic Reviews and Meta-analyses
19 (<http://www.prisma-statement.org>) guidelines for meta-analyses of observational studies.

20 Inclusion criteria for studies were as follows: (1) task-related fMRI data of adult rMDD and
21 MDD patients (18-65 years) were compared to those of HCs; (2) results were exhibited using
22 Talairach coordinates or Montreal Neurological Institute (MNI); (3) a whole-brain analysis was
23 conducted to mitigate bias in the regions that were reported; and (4) whenever articles reported

1 findings from the same task paradigm that included samples overlapped, the one with the greatest
2 number of subjects was selected. Studies were not included if (1) task-related fMRI was not used to
3 compare brain activation between rMDD/MDD patients and HCs at the voxel level, (2) they
4 included duplicated datasets, or (3) did not exhibit peak coordinates. A total of 9212 studies on
5 MDD and 1,006 studies on rMDD were identified. After applying the inclusion and exclusion
6 criteria, 18 studies on rMDD and 120 studies on MDD were found to fit the requirements and were
7 included in the meta-analysis (Fig. S1).

8 **2.2 Voxel-wise meta-analysis**

9 The anisotropic effect-size signed differential mapping (SDM) software
10 (<http://www.sdmproject.com/software/>) was used to perform a voxel-wise meta-analysis (Radua et
11 al., 2012) between patients and HCs for rMDD and MDD separately. All the analytical processes in
12 this study were conducted following the SDM tutorial. The SDM used the fitting method of
13 restricted maximum-likelihood estimation of the variance to find an appropriate balance between
14 lack of bias and efficiency (Radua and Mataix-Cols, 2009; Radua et al., 2012). First, peak
15 coordinates of brain activation differences between rMDD/MDD patients and HCs were extracted
16 from each included study. Next, variance and effect-size signed map for each dataset within a gray
17 matter mask according to the peak coordinates and their effect sizes were generated by an
18 anisotropic nonnormalized Gaussian kernel of 20-mm full-width at half-maximum (FWHM) to
19 optimize the specificity and sensitivity of the analysis. Third, a mean map was created by the
20 voxel-wise calculation of the mean of the dataset maps, weighted by the squared root of the sample
21 size of each dataset; with this approach, studies with large sample sizes had a greater weighting of
22 their results. Ultimately, the results were determined to be statistically significant through standard
23 permutation tests and a threshold of $p = 0.005$ with SDM z score ≥ 1 and a cluster-level threshold

1 of 10 voxels in the current voxel-wise meta-analysis (Müller et al., 2018).

2 In 2010, the US National Institute of Mental Health proposed the Research Domain Criteria
3 (RDoC) framework (Insel et al., 2010). The RDoC is the most appropriate framework for
4 classifying the array of criteria used in research and enables a more comprehensive interpretation of
5 results in terms of dysfunction in clearly defined brain activity processes. According to the RDoC,
6 task-related fMRI studies involving comparisons between HCs and MDD/rMDD patients can be
7 divided into five domains (as classified in Table S1 of the Supplementary Materials).

8 The results from all tasks and cognitive domains used in the primary experiments were pooled
9 together to generate the modeled activation maps. The RDoC framework (Insel et al., 2010)
10 classifies neurocognitive tasks based on their presumed association with known brain circuits in a
11 principled way. Although there is some relationship between tasks and brain areas, it is not a
12 one-to-one correspondence. The association between brain function and structure has been
13 described both as pluripotent (one to many) and degenerate (many to one). This means that
14 any given task paradigm can engage brain areas outside these predicted by the cognitive
15 components attributed to that specific task, while a single brain region may be excited by different
16 tasks that may underlying a distinct cognitive mechanism (Pessoa, 2014; Price and Friston, 2005).

17 Next, to assess the effects between rMDD and MDD patients, a linear meta-regression model was
18 conducted to analyze group comparisons. The results of this group comparison were masked by the
19 findings of an initial model that included both the rMDD and MDD groups; thus, the evaluation
20 only included the main group effect. Only differences that survived a voxel-level threshold of $p <$
21 0.005 , a cluster-level threshold of $k \geq 10$ voxels, and an SDM-Z value threshold of 1 were reported.
22 These threshold corresponded to $p < 0.05$ corrected for multiple comparisons in a meta-analysis
23 (Norman et al., 2016; Radua et al., 2014, 2010; Schulze et al., 2019).

1 Finally, the overlap of neural activation differences between rMDD and MDD patients via the
2 combination of thresholded meta-analytic result maps was investigated. This multimodal analysis
3 function of the SDM statistical package enabled us to identify brain areas in which both rMDD and
4 MDD patients share characteristics that differ from those of HCs ((rMDD vs. HCs) versus (MDD vs.
5 HCs)), while taking into account error in the estimation of the magnitude of these differences. The
6 default parameters of SDM were used (peak $p < 0.00025$, cluster size of >10) (Radua et al., 2010).

7 **2.3 Heterogeneity and Publication Bias**

8 A random effects model with I^2 statistics was used to conduct a heterogeneity analysis in order to
9 explore unexplained variability among studies. The I^2 statistic was utilized to evaluate the
10 percentage of variation due to heterogeneity other than chance. Extreme heterogeneity corresponds
11 to I^2 values of 75-100%, large heterogeneity corresponds to I^2 values of 50-75%, moderate
12 heterogeneity corresponds to I^2 values of 25-50%, and low heterogeneity corresponds to I^2 values of
13 0-25%. Using the default SDM kernel size and thresholds (FWHM = 20 mm, $p = 0.005$,
14 uncorrected for the false discovery rate (FDR), peak height $Z = 1$, cluster extent = 10 voxels), we
15 obtained heterogeneous brain regions (Amad et al., 2019; Gong et al., 2020; Radua et al., 2014).
16 Egger's test was used to evaluate underlying publication bias, with a p value less than 0.05
17 indicating significant (Egger et al., 1997).

18 **2.4 Reliability and Meta-regressions**

19 To assess the robustness of the rMDD and MDD results, a jackknife sensitivity analysis was
20 conducted which entailed excluding one study from the analyses (Radua and Mataix-Cols, 2009).
21 Finally, we used meta-regression analyses, which are based on simple linear regression models to
22 estimate the effect of age, female percentage, the number of depressive episodes, the severity of
23 depressive symptoms and duration of illness on the effect sizes found in the rMDD and MDD

1 meta-analyses. Meta-regression analyses were conducted only when brain areas of rMDD or MDD
2 patients showed significant hypoactivation or hyperactivation compared with those of HCs.

3 **3. Results**

4 **3.1. Study Characteristics**

5 A total of 18 studies and 24 experiments were included, with observations from 440 rMDD
6 patients and 456 HCs. Supplementary. The included studies reported neural activation differences
7 between 3079 MDD patients and 3214 HCs using data from 120 studies which included 147
8 experiments. Detailed demographic characteristics and study data for both MDD and rMDD can be
9 found in Supplementary Table S2 and S3.

10 **3.2. Neural Activation Differences in the Main Meta-analysis**

11 **3.2.1. rMDD versus HCs**

12 As shown in Fig. 1A and Table 1, compared with HCs, patients with rMDD indicated
13 significantly increased neural activation in the right inferior network extending to the MTG and
14 STG, right striatum, left median cingulate, and right anterior thalamic projections. They also
15 revealed decreased activation in the right MTG, left superior frontal gyrus (SFG), and left cuneus
16 cortex relative to that of HCs. These brain regions show low between-study heterogeneity. Egger's
17 tests of publication bias were nonsignificant (all p values > 0.05) except in the right inferior
18 network ($p = 0.007$). Jackknife sensitivity analyses revealed that abnormal neural activation in the
19 right inferior network, SFG, and right MTG were found in all 24 analyses. The other activated or
20 deactivated brain areas remained replicable, as they were significant in at least 16/24 of the
21 experiments (Table 1).

22 **3.2.2. MDD versus HCs**

23 As presented in Fig. 1B and Table 2, the meta-analytic brain map revealed both increased and

1 decreased neural activation in MDD patients compared with HCs. MDD patients showed increased
2 neural activation in the bilateral STG, left insula, left hippocampus, left median network/cingulum
3 (extending to the hippocampus), bilateral inferior frontal gyrus (IFG), right inferior network, and
4 right middle frontal gyrus and decreased neural activation in the left inferior parietal gyrus
5 (extending to the occipital cortex), right lenticular nucleus/putamen, left middle frontal gyrus
6 (including the dorsolateral prefrontal cortex), right thalamus, and bilateral caudate nucleus. These
7 brain areas did not show obvious between-study heterogeneity. Egger's tests of publication bias
8 were nonsignificant (all p values > 0.05) except for the right inferior network (p values = 0.038).
9 The jackknife sensitivity analysis showed that in MDD patients, the most robust brain area patterns
10 were increases in neural activation in the right STG and left insula and a decrease in neural
11 activation in the left inferior parietal gyrus, as they were significant in all 147 analyses. The
12 increased or decreased neural activation in the other brain regions remained replicable, as they were
13 significant in at least 126/147 of the experiments (Table 2).

14 **3.2.3. (rMDD vs. HCs) versus (MDD vs. HCs)**

15 As illustrated in Fig. 1C and Table 3, the meta-analytic brain map illustrated both increased and
16 decreased neural activation in rMDD patients relative to MDD patients. Relative to MDD patients,
17 rMDD patients showed increased neural activation in the right MTG, right striatum, right caudate,
18 left inferior parietal, and left median cingulate gyrus and decreased neural activation in the left
19 cuneus cortex, right MTG, and left SFG (including the prefrontal cortex). These brain areas did not
20 reveal obvious between-study heterogeneity. Egger's tests also showed that there was no publication
21 bias in each brain region (all p values > 0.05) (Table 3).

22 **3.2.4. (rMDD vs. HCs) and (MDD vs. HCs) Conjunction**

23 Conjunction analysis showed that compared with HCs, both rMDD and MDD patients had

1 increased neural activation in the right temporal pole and right STG (Fig. 1D; right temporal pole:
2 peak MNI = 54, 6, -14; $p < 0.001$; 288 voxels; right superior temporal gyrus: peak MNI = 50, -8,
3 -12; $p < 0.001$; 282 voxels).

4 **3.3. Meta-regression Analysis**

5 Meta-regression analyses revealed that percentage of females with MDD (available in all but six
6 studies) was positively related with brain activation in the right lenticular nucleus/putamen (peak
7 coordinates: $x = 30$, $y = 14$, $z = 8$; SDM + 1 per 0.004 point increase in the percentage of females, p
8 = 0.0101) (Supplementary Fig. S2). We found no significant associations between the severity of
9 depressive symptoms, mean age, or abnormal brain activity in patients with MDD. In rMDD
10 patients, no significant associations were found between the number of depressive episodes,
11 severity of depressive symptoms, average age, percentage of females, and brain regions with
12 abnormal activation.

13 **4. Discussion**

14 To the best of our knowledge, this study is the first meta-analysis to investigate the common and
15 distinct neural activation patterns of patients with MDD and patients with rMDD in task-related
16 whole-brain fMRI studies. We found that MDD and rMDD patients shared increased neural
17 activation in the right temporal pole and the right STG. Several brain regions, including the right
18 MTG, left inferior parietal, prefrontal cortex, left SFG and the striatum differed significantly
19 between MDD patients and rMDD patients.

20 **Comparison of rMDD Patients and HCs**

21 Similar to previous task-related fMRI meta-analyses of rMDD patients (Wang et al., 2022), our
22 results presented that compared with HCs, patients with rMDD showed significantly abnormal
23 neural activity in the left inferior parietal gyrus, left SFG, and right MTG, which play an important

1 role in sensory perception, emotional control and cognitive functions, respectively. At present, the
2 emotion regulation theory (van Kleef et al., 2022), and the cognitive model theory (Disner et al.,
3 2011) are main hypotheses about the neuropathological mechanism of depression. Specifically, the
4 left inferior parietal gyrus, SFG and MTG contribute to emotional control and cognitive function in
5 MDD patients (Gong et al., 2020; Zheng et al., 2021). For rMDD individuals, stress may trigger a
6 potential dysfunctional schema, in which the way of external and internal information is changed
7 such that MDD patients prefer information with a certain emotional valence (or find such
8 information aversive) in cognitive bias, thus promoting the recurrence of depressive mood states
9 (Beck, 2008; van Kleef et al., 2022). Dysfunctional regulatory control and cognitive function may
10 then prolong the experience of negative emotion, leading patients to spiral into a persistent
11 depressed mood and finally a new depressive episode (Berking et al., 2014). Thus, disruptions in
12 the processing and regulation of emotional information are important to understand how even mild
13 adverse events may lead to subsequent MDD episodes. To a certain extent, our results of altered
14 neural activation in task-related fMRI suggested that abnormalities in specific brain areas of rMDD
15 patients can be used as biological indicators for predicting the recurrence of depression.

16 **Comparison of MDD Patients and HCs**

17 Our results are consistent with previous task-related fMRI studies conducted in MDD patients,
18 which reported that compared with those of HCs, the STG, insula, middle frontal gyrus (including
19 the dorsolateral prefrontal cortex), IFG, and limbic system showed hypoactivation or
20 hyperactivation in MDD patients (Diener et al., 2012; Fitzgerald et al., 2008; Müller et al., 2017).
21 The insula is adjacent to the frontal lobe, temporal lobe, parietal lobe and limbic system, which are
22 implicated in regulatory, affective, and disparate cognitive functions, including emotional responses,
23 interoceptive awareness, and empathic processes (Gong et al., 2020). Moreover, many resting-state

1 fMRI studies have shown altered functional connectivity in MDD patients involving the
2 aforementioned abnormal neural activation, including the default mode network (DMN), salience
3 network (SN), and central executive network (CEN) (Sha et al., 2019). The dynamic switching
4 between the DMN and CEN involved in these brain regions facilitates access to cognitive resources,
5 such as working memory and attention, when a salient event is detected. Thus, altered strength in
6 the connection in these networks influences cognitive deficits in MDD patients (Gong et al., 2020).
7 Previous task-based fMRI studies reported altered activation of the insula, dorsolateral prefrontal
8 cortex, IFG, and limbic system during emotional processing tasks and executive functioning tasks
9 in the brains of MDD patients (Miller et al., 2015a; Yang et al., 2022), which may partly explain the
10 abnormalities in emotional and cognitive integration. In addition, altered activity in these brain
11 areas occurs with a number of treatments for depression, including cognitive behavior therapy, deep
12 brain stimulation, and medication, indicating a role for these regions in mediating the antidepressant
13 response and remission more generally (McGrath et al., 2013). Moreover, the meta-analysis of
14 current structural morphometric studies also revealed abnormal gray matter volume in these brain
15 regions in MDD patients (Sha et al., 2019; Zhang et al., 2016). Therefore, structural and functional
16 abnormalities in these areas may be critical neurobiological features of MDD.

17 **Differences between rMDD and MDD Patients**

18 Consistent with previous task-related research, we observed different prefrontal cortex and SFG
19 activation in MDD patients versus rMDD patients (Ming et al., 2017). Several resting-state fMRI
20 studies also reported the aforementioned neural activity differences between MDD and rMDD
21 patients (Yang et al., 2018; Young et al., 2014). Moreover, there is evidence of a negative
22 association between the severity of depressive symptoms and reduced fMRI response of the
23 prefrontal cortex and SFG in unaffected first-degree relatives of MDD and rMDD patients (Philippi

1 et al., 2018; Watters et al., 2019). Based on the above results, it may be indicated that with the relief
2 of depressive symptoms, abnormal activation of brain regions related to depressive symptoms also
3 changes, which provides strong evidence for finding therapeutic targets for depression. It should be
4 pointed out that the current research evidence from fMRI combined with artificial intelligence
5 reported that depression is divided into different biotypes (Liang et al., 2020), and depression
6 symptoms can actually be divided into different subgroups. However, to the best of our knowledge,
7 there is no research exploring the relationship between the subgroups of depressive symptoms and
8 abnormal neural activation, so it is necessary for future fMRI research to focus on the subgroups of
9 depressive symptoms and explore their corresponding abnormal neural activation. This research is
10 crucial for finding neurobiological targets for the precise treatment of depression.

11 Previous studies revealed that fMRI responses in the MTG, cingulate cortex, and prefrontal
12 cortex during various tasks and resting-state valence significantly predicted posttreatment symptom
13 improvement in individuals with MDD (Gao et al., 2022; Harris et al., 2022; Karim et al., 2018;
14 Miller et al., 2015b). Our results also showed the different fMRI responses between rMDD and
15 MDD patients in the MTG, cingulate cortex, and prefrontal cortex, which suggested that such
16 differences may be due to neurological reactions after or during antidepressant treatment. However,
17 most of the patients in the MDD group we included were receiving antidepressant treatment, while
18 in the rMDD group, in only three studies were rMDD individuals receiving antidepressant treatment.
19 Thus, an important direction of future research is to explore the differences in neural activation
20 between first-episode and drug-naive MDD patients and rMDD patients who have stopped
21 medication for a long period of time. The comparisons have important reference significance for
22 finding the corresponding targets of specific antidepressant treatments, such as specific
23 antidepressant drug therapy, physical therapy, and psychotherapy.

1 **Common Effects in Both rMDD and MDD Patients**

2 The conjunction analysis suggested that neural activations of the right STG and right temporal
3 pole were higher in both rMDD and MDD patients than in HCs, which may indicate a consistent
4 inherent abnormal activity pattern across MDD states. Previous task-related fMRI studies
5 implicating MDD and rMDD individuals also suggested abnormal neural activation of the right
6 STG and right temporal pole (Dichter et al., 2012; Rai et al., 2021), which was further confirmed in
7 our meta-analysis by comparing MDD and rMDD patients with HCs. The common disruptions in
8 neural activation within both MDD and rMDD patients pose an interesting question for the study on
9 the neuropathological mechanism of MDD: are the anomalously activated brain areas found in both
10 conditions acquired alterations after MDD or intrinsic to MDD? If these abnormalities change after
11 MDD acquisition and persist, they may represent objective neurophysiological markers for the
12 diagnosis of depression. If these differences are intrinsic changes in the MDD population, this
13 would infer that abnormal activation of related brain areas persists before the onset of MDD, during
14 the course of MDD and after MDD remission, which may provide potential neurobiological
15 markers for early screening of MDD. To the best of our knowledge, no longitudinally neuroimaging
16 study has examined brain changes throughout the course of MDD (i.e., before, during and after
17 remission); such studies are urgently needed to comprehensively understand the underlying
18 mechanisms of MDD.

19 **Limitation**

20 The current study was limited in some respects. The included studies were exclusive to those in
21 adults; our findings may not be extrapolated to elderly individuals or children. Second, anomalous
22 brain activation may gradually subside with the prolongation of the remission period (Ming et al.,
23 2017), but only a few rMDD studies provided remission period information, which led us to fail to

1 explore the impact of this aspect. Furthermore, the duration of MDD illness also affects neural
2 activation (Zhou et al., 2017), but our meta-regression analysis did not find an effect of MDD
3 course on neural activation. The remission period and the duration of illness are important issues
4 that should be explored in future studies. Finally, the varieties in neuroimaging sequence acquisition
5 parameters, such as the number of coil channels, resolution, and field strength can lead to errors in
6 statistical modelling. To mitigate these errors, it is essential to establish industry specifications akin
7 to the Diagnostic and Statistical Manual of Mental Disorders (DSM) system to standardize
8 methodology and ensure the results are applicable across different fields.

9 **5. Conclusion**

10 In conclusion, our meta-analysis shows that rMDD and MDD patients display a common pattern
11 of aberrant task-related neural activation, which includes the right temporal pole and STG.
12 Moreover, both rMDD and MDD patients exhibit distinct patterns of neural activation changes
13 predominantly in the MTG, prefrontal cortex, and striatum. These findings seem to imply that the
14 brain functions of rMDD and MDD patients have both similar and distinctive features and expands
15 on a growing literature examining task-related fMRI in rMDD and MDD patients. Our results
16 provide useful insights for understanding the potential neuropathology of brain dysfunction in
17 MDD patients, developing more targeted and efficacious treatment and intervention strategies, and
18 more importantly, providing potential neuroimaging targets for the early screening of MDD.

References

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44

Amad, A., Radua, J., Vaiva, G., Williams, S.C., Fovet, T., 2019. Similarities between borderline personality disorder and post traumatic stress disorder: Evidence from resting-state meta-analysis. *Neuroscience and biobehavioral reviews* 105, 52-59.

Beck, A.T., 2008. The evolution of the cognitive model of depression and its neurobiological correlates. *The American journal of psychiatry* 165, 969-977.

Berking, M., Wirtz, C.M., Svaldi, J., Hofmann, S.G., 2014. Emotion regulation predicts symptoms of depression over five years. *Behaviour research and therapy* 57, 13-20.

Dichter, G.S., Kozink, R.V., McClernon, F.J., Smoski, M.J., 2012. Remitted major depression is characterized by reward network hyperactivation during reward anticipation and hypoactivation during reward outcomes. *Journal of affective disorders* 136, 1126-1134.

Diener, C., Kuehner, C., Brusniak, W., Ubl, B., Wessa, M., Flor, H., 2012. A meta-analysis of neurofunctional imaging studies of emotion and cognition in major depression. *NeuroImage* 61, 677-685.

Disner, S.G., Beevers, C.G., Haigh, E.A., Beck, A.T., 2011. Neural mechanisms of the cognitive model of depression. *Nature reviews. Neuroscience* 12, 467-477.

Egger, M., Davey Smith, G., Schneider, M., Minder, C., 1997. Bias in meta-analysis detected by a simple, graphical test. *BMJ : British medical journal* 315, 629-634.

Fitzgerald, P.B., Laird, A.R., Maller, J., Daskalakis, Z.J., 2008. A meta-analytic study of changes in brain activation in depression. *Human brain mapping* 29, 683-695.

Gao, C., Xu, Z., Tan, T., et al., 2022. Combination of spontaneous regional brain activity and HTR1A/1B DNA methylation to predict early responses to antidepressant treatments in MDD. *Journal of affective disorders* 302, 249-257.

Gong, J., Wang, J., Qiu, S., et al., 2020. Common and distinct patterns of intrinsic brain activity alterations in major depression and bipolar disorder: voxel-based meta-analysis. *Translational psychiatry* 10, 353.

Harris, J.K., Hassel, S., Davis, A.D., et al., 2022. Predicting escitalopram treatment response from pre-treatment and early response resting state fMRI in a multi-site sample: A CAN-BIND-1 report. *NeuroImage. Clinical* 35, 103120.

Huang, Y., Wang, Y., Wang, H., et al., 2019. Prevalence of mental disorders in China: a cross-sectional epidemiological study. *The lancet. Psychiatry* 6, 211-224.

Insel, T., Cuthbert, B., Garvey, M., et al., 2010. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. *The American journal of psychiatry* 167, 748-751.

Janiri, D., Moser, D.A., Doucet, G.E., et al., 2020. Shared Neural Phenotypes for Mood and Anxiety Disorders: A Meta-analysis of 226 Task-Related Functional Imaging Studies. *JAMA psychiatry* 77, 172-179.

Kambeitz, J., Cabral, C., Sacchet, M.D., et al., 2017. Detecting Neuroimaging Biomarkers for Depression: A Meta-analysis of Multivariate Pattern Recognition Studies. *Biological psychiatry* 82, 330-338.

Karim, H.T., Wang, M., Andreescu, C., et al., 2018. Acute trajectories of neural activation predict remission to pharmacotherapy in late-life depression. *NeuroImage. Clinical* 19, 831-839.

Keren, H., Callaghan, G., et al., 2018. Reward Processing in Depression: A Conceptual and Meta-Analytic Review Across fMRI and EEG Studies. *The American journal of psychiatry* 175, 1111-1120.

Lemke, H., Probst, S., Warneke, A., et al., 2022. The Course of Disease in Major Depressive Disorder Is Associated With Altered Activity of the Limbic System During Negative Emotion Processing. *Biological psychiatry. Cognitive neuroscience and neuroimaging* 7, 323-332.


Li, L., Li, R., Shen, F., et al., 2022. Negative bias effects during audiovisual emotional processing in major depression disorder. *Human brain mapping* 43, 1449-1462.

Liang, S., Deng, W., Li, X., et al., 2020. Biotypes of major depressive disorder: Neuroimaging evidence from resting-state default mode network patterns. *NeuroImage. Clinical* 28, 102514.

- 1 Malhi, G.S., Das, P., Outhred, T., Bryant, R.A., Calhoun, V., Mann, J.J., 2020. Default mode dysfunction underpins suicidal activity
2 in mood disorders. *Psychological medicine* 50, 1214-1223.
- 3 McGrath, C.L., Kelley, M.E., Holtzheimer, P.E., et al., 2013. Toward a neuroimaging treatment selection biomarker for major
4 depressive disorder. *JAMA psychiatry* 70, 821-829.
- 5 Miller, C.H., Hamilton, J.P., Sacchet, M.D., Gotlib, I.H., 2015a. Meta-analysis of Functional Neuroimaging of Major Depressive
6 Disorder in Youth. *JAMA psychiatry* 72, 1045-1053.
- 7 Miller, S., McTeague, L.M., Gyurak, A., et al., 2015b. COGNITION-CHILDHOOD MALTREATMENT INTERACTIONS IN THE
8 PREDICTION OF ANTIDEPRESSANT OUTCOMES IN MAJOR DEPRESSIVE DISORDER PATIENTS: RESULTS
9 FROM THE iSPOT-D TRIAL. *Depression and anxiety* 32, 594-604.
- 10 Ming, Q., Zhong, X., Zhang, X., et al., 2017. State-Independent and Dependent Neural Responses to Psychosocial Stress in Current
11 and Remitted Depression. *The American journal of psychiatry* 174, 971-979.
- 12 Moriarty, A.S., Meader, N., Snell, K., et al., 2022. Predicting relapse or recurrence of depression: systematic review of prognostic
13 models. *The British journal of psychiatry : the journal of mental science* 221, 448-458.
- 14 Müller, V.I., Cieslik, E.C., Laird, A.R., et al., 2018. Ten simple rules for neuroimaging meta-analysis. *Neuroscience and
15 biobehavioral reviews* 84, 151-161.
- 16 Müller, V.I., Cieslik, E.C., Serbanescu, I., Laird, A.R., Fox, P.T., Eickhoff, S.B., 2017. Altered Brain Activity in Unipolar Depression
17 Revisited: Meta-analyses of Neuroimaging Studies. *JAMA psychiatry* 74, 47-55.
- 18 Norman, L.J., Carlisi, C., Lukito, S., et al., 2016. Structural and Functional Brain Abnormalities in Attention-Deficit/Hyperactivity
19 Disorder and Obsessive-Compulsive Disorder: A Comparative Meta-analysis. *JAMA psychiatry* 73, 815-825.
- 20 Palmer, S.M., Crewther, S.G., Carey, L.M., 2014. A meta-analysis of changes in brain activity in clinical depression. *Frontiers in
21 human neuroscience* 8, 1045.
- 22 Pessoa, L., 2014. Understanding brain networks and brain organization. *Physics of life reviews* 11, 400-435.
- 23 Philippi, C.L., Cornejo, M.D., Frost, C.P., et al., 2018. Neural and behavioral correlates of negative self-focused thought associated
24 with depression. *Human brain mapping* 39, 2246-2257.
- 25 Price, C.J., Friston, K.J., 2005. Functional ontologies for cognition: The systematic definition of structure and function. *Cognitive
26 neuropsychology* 22, 262-275.
- 27 Radua, J., Mataix-Cols, D., 2009. Voxel-wise meta-analysis of grey matter changes in obsessive-compulsive disorder. *The British
28 journal of psychiatry : the journal of mental science* 195, 393-402.
- 29 Radua, J., Mataix-Cols, D., Phillips, M.L., et al., 2012. A new meta-analytic method for neuroimaging studies that combines reported
30 peak coordinates and statistical parametric maps. *European psychiatry : the journal of the Association of European
31 Psychiatrists* 27, 605-611.
- 32 Radua, J., Rubia, K., Canales-Rodríguez, E.J., Pomarol-Clotet, E., Fusar-Poli, P., Mataix-Cols, D., 2014. Anisotropic kernels for
33 coordinate-based meta-analyses of neuroimaging studies. *Frontiers in psychiatry* 5, 13.
- 34 Radua, J., van den Heuvel, O.A., Surguladze, S., Mataix-Cols, D., 2010. Meta-analytical comparison of voxel-based morphometry
35 studies in obsessive-compulsive disorder vs other anxiety disorders. *Archives of general psychiatry* 67, 701-711.
- 36 Rai, S., Griffiths, K., Breukelaar, I.A., et al., 2021. Investigating neural circuits of emotion regulation to distinguish euthymic patients
37 with bipolar disorder and major depressive disorder. *Bipolar disorders* 23, 284-294.
- 38 Schulze, L., Schulze, A., Renneberg, B., Schmahl, C., Niedtfeld, I., 2019. Neural Correlates of Affective Disturbances: A
39 Comparative Meta-analysis of Negative Affect Processing in Borderline Personality Disorder, Major Depressive Disorder,
40 and Posttraumatic Stress Disorder. *Biological psychiatry. Cognitive neuroscience and neuroimaging* 4, 220-232.
- 41 Sha, Z., Wager, T.D., Mechelli, A., He, Y., 2019. Common Dysfunction of Large-Scale Neurocognitive Networks Across Psychiatric
42 Disorders. *Biological psychiatry* 85, 379-388.
- 43 Smoski, M.J., Keng, S.L., Schiller, C.E., Minkel, J., Dichter, G.S., 2013. Neural mechanisms of cognitive reappraisal in remitted
44 major depressive disorder. *Journal of affective disorders* 151, 171-177.
- 45 Spets, D.S., Slotnick, S.D., 2021. Are there sex differences in brain activity during long-term memory? A systematic review and
46 fMRI activation likelihood estimation meta-analysis. *Cognitive neuroscience* 12, 163-173.

- 1 Thalamuthu, A., Mills, N.T., Berger, K., et al., 2022. Genome-wide interaction study with major depression identifies novel variants
2 associated with cognitive function. *Molecular psychiatry* 27, 1111-1119.
- 3 Trettin, M., Dvořák, J., Hilke, M., et al., 2022. Neuronal response to high negative affective stimuli in major depressive disorder: An
4 fMRI study. *Journal of affective disorders* 298, 239-247.
- 5 van Kleef, R.S., Marsman, J.C., van Valen, E., Bockting, C., Aleman, A., van Tol, M.J., 2022. Neural basis of positive and negative
6 emotion regulation in remitted depression. *NeuroImage. Clinical* 34, 102988.
- 7 Wang, X.L., Du, M.Y., Chen, T.L., et al., 2015. Neural correlates during working memory processing in major depressive disorder.
8 *Progress in neuro-psychopharmacology & biological psychiatry* 56, 101-108.
- 9 Wang, Z., Zou, Z., Xiao, J., et al., 2022. Task-related neural activation abnormalities in patients with remitted major depressive
10 disorder: a coordinate-based meta-analysis. *Neuroscience and biobehavioral reviews* 10, 353.
- 11 Watters, A.J., Carpenter, J.S., Harris, A., Korgaonkar, M.S., Williams, L.M., 2019. Characterizing neurocognitive markers of familial
12 risk for depression using multi-modal imaging, behavioral and self-report measures. *Journal of affective disorders* 253,
13 336-342.
- 14 Yang, C., Zhang, A., Jia, A., et al., 2018. Identify abnormalities in resting-state brain function between first-episode, drug-naive
15 major depressive disorder and remitted individuals: a 3-year retrospective study. *Neuroreport* 29, 907-916.
- 16 Yang, X., Su, Y., Yang, F., et al., 2022. Neurofunctional mapping of reward anticipation and outcome for major depressive disorder: a
17 voxel-based meta-analysis. *Psychological medicine* , 1-14.
- 18 Young, K.D., Bellgowan, P.S., Bodurka, J., Drevets, W.C., 2014. Neurophysiological correlates of autobiographical memory deficits
19 in currently and formerly depressed subjects. *Psychological medicine* 44, 2951-2963.
- 20 Yu, H., Meng, Y.J., Li, X.J., et al., 2019. Common and distinct patterns of grey matter alterations in borderline personality disorder
21 and bipolar disorder: voxel-based meta-analysis. *The British journal of psychiatry : the journal of mental science* 215,
22 395-403.
- 23 Zhang, H., Li, L., Wu, M., et al., 2016. Brain gray matter alterations in first episodes of depression: A meta-analysis of whole-brain
24 studies. *Neuroscience and biobehavioral reviews* 60, 43-50.
- 25 Zheng, R., Zhang, Y., Yang, Z., Han, S., Cheng, J., 2021. Reduced Brain Gray Matter Volume in Patients With First-Episode Major
26 Depressive Disorder: A Quantitative Meta-Analysis. *Frontiers in psychiatry* 12, 671348.
- 27 Zhou, M., Hu, X., Lu, L., et al., 2017. Intrinsic cerebral activity at resting state in adults with major depressive disorder: A
28 meta-analysis. *Progress in neuro-psychopharmacology & biological psychiatry* 75, 157-164.
- 29
- 30

Figure. Brain regions showed significant task-related neural activation differences between groups based on the meta-analyses. Meta-analyses results regarding A) task-related neural activation difference between rMDD and HCs, B) task-related neural activation difference MDD and HCs, C) task-related neural activation difference between rMDD and MDD (vs. HCs), as well as D) conjunction of rMDD and MDD (vs. HCs). Areas with decreased task-related neural activation value are displayed in blue, and areas with increased task-related neural activation value are displayed in red. The color bar indicates the maximum and minimum SDM-Z values.



Abbreviation: HCs, healthy controls; MDD, major depressive disorder; rMDD, remitted major depressive disorder; SDM seed-based *d* mapping.

Table 1. Clusters showing differences between rMDD and HC.

Local maximum region	Peak MNI coordinate (x, y, z)	SDM-Z	p	Cluster size / voxels	Breakdown (Number of voxels)	Jackknife sensitivity	Heterogeneity I^2	Publish bias Egger's tests
rMDD > HC								
Right inferior network, inferior longitudinal fasciculus	48, -14, -22	2.436	0.000015497	862	Right middle temporal gyrus, BA 21 (257) Right inferior network, inferior longitudinal fasciculus (230) Right inferior temporal gyrus, BA 20 (199) Right temporal pole, middle temporal gyrus, BA 21 (50) Right superior temporal gyrus, BA 21 (36) Right fusiform gyrus, BA 20 (31)	24/24	0.30%	0.007
Right striatum	24, 12, 2	1.818	0.000500619	122	Right striatum (87) Right lenticular nucleus, putamen, BA 48 (24)	23/24	0.10%	0.228
Left median cingulate / paracingulate gyrus, BA 23	-4, -16, 44	1.562	0.002420425	53	Left median cingulate / paracingulate gyrus, BA 23 (52)	22/24	0.0%	0.688
Right anterior thalamic projections	18, 14, 10	1.527	0.002941668	26	Right anterior thalamic projections (25)	23/24	0.0%	0.833
rMDD < HC								
Left superior frontal gyrus	2, 58, 28	-1.663	0.000206411	670	Left superior frontal gyrus, BA 10 (330) Right superior frontal gyrus, BA 10 (191) Corpus callosum (47) Left superior frontal gyrus, BA 32 (45) Right superior frontal gyrus, BA 32 (31)	24/24	25.0%	0.126
Right middle temporal gyrus, BA 39	52, -68, 14	-1.338	0.001641154	155	Right middle temporal gyrus, BA 37 (119) Right middle temporal gyrus, BA 39 (28)	24/24	11.9%	0.698
Left cuneus cortex, BA 18	-6, -84, 28	-1.217	0.003602266	11	Left cuneus cortex, BA 18 (11)	16/24	2.1%	0.897

rMDD, remitted major depressive disorder; HC, healthy control; BA, Brodman areas; MNI, montreal neurological institute.

Table 2. Clusters showing differences between MDD and HC.

Local maximum region	Peak MNI coordinate (x, y, z)	SDM-Z	p	Cluster size / voxels	Breakdown (Number of voxels)	Jackknife sensitivity	Heterogeneity I^2	Publish bias Egger's tests
MDD > HC								
Right superior temporal gyrus, BA 22	62, -18, 6	1.690	0.000206411	646	Right superior temporal gyrus, BA 22 (358) Corpus callosum (119) Right superior temporal gyrus, BA 48 (86) Right rolandic operculum (54) Right superior temporal gyrus, BA 42 (45) Right rolandic operculum, BA 22 (29) Right postcentral gyrus, BA 48 (10)	147/147	0.0%	0.606
Left insula, BA 48	-40, -4, -16	1.819	0.000067115	305	Left superior gyrus, BA 48 (56) Left insula, BA 48 (33) Left inferior network, uncinata fasciculus (32) Anterior commissure (22)	147/147	0.0%	0.538
Left parahippocampal gyrus, BA 37	-26, -36, -12	1.541	0.000588357	148	Left median network, cingulum (58) Left hippocampus, BA 37 (24) Left parahippocampal gyrus, BA 37 (30)	142/147	0.0%	0.212
Left inferior frontal gyrus, opercular part, BA 48	-54, 14, 6	1.547	0.000572860	102	Left inferior frontal gyrus, opercular part, BA 48 (61) Left inferior frontal gyrus, triangular part, BA 48 (29)	139/147	0.0%	0.786
Right inferior frontal gyrus, opercular part, BA 44	56, 16, 14	1.352	0.001816630	79	Right inferior frontal gyrus, opercular part, BA 44 (59)	138/147	0.0%	0.675
Left median network, cingulum	-30, -16, -24	1.503	0.000774145	59	Left median network, cingulum (26) Left inferior network, inferior longitudinal fasciculus (15) Left hippocampus, BA 20 (15)	134/147	0.0%	0.263
Right middle frontal	38, 20, 52	1.490	0.000841200	51	Right middle frontal gyrus, BA 9 (37)	134/147	0.0%	0.165

gyrus, BA 9									
Left inferior frontal gyrus, triangular part, BA 45	-42, 34, 26	1.388	0.001460493	51	Left inferior frontal gyrus, triangular part, BA 45 (26)	130/147	0.0%	0.231	
Right inferior network, inferior longitudinal fasciculus	10, -80, -6	1.366	0.001677275	46	Left middle frontal gyrus, BA 45 (12) Right inferior network, inferior longitudinal fasciculus (41)	126/147	0.0%	0.038	
Left superior temporal gyrus, BA 48	-58, -10, 0	1.285	0.002647519	41	Left superior temporal gyrus, BA 48 (30)	128/147	0.0%	0.138	
MDD < HC									
Left inferior parietal gyrus, BA 7	-32, -68, 44	-2.439	~0	1328	Left middle occipital gyrus, (382) Left inferior parietal gyrus, BA 7 (305) Left superior parietal gyrus, BA 7 (176) Left angular gyrus, (257) Corpus callosum (56) Left superior longitudinal fasciculus II (48) Left superior occipital gyrus, BA 19 (52)	147/147	0.0%	0.283	
Right lenticular nucleus, putamen, BA 48	30, 14, 8	-1.458	0.000645101	325	Right lenticular nucleus, putamen, BA 48 (145) Right insula, BA 48 (62) Right superior longitudinal fasciculus III (22) Right striatum (19)	145/147	0.0%	0.151	
Left middle frontal gyrus, BA 6	-24, 2, 56	-1.668	0.000149667	254	Left middle frontal gyrus, BA 8 (76) Left precentral gyrus, BA 6 (54) Left middle frontal gyrus, BA 6 (52) Left superior frontal gyrus, dorsolateral, BA 6 (44) Corpus callosum (17)	144/147	0.0%	0.696	
Corpus callosum	20, -30, 8	-1.606	0.000237405	131	Right thalamus (55) Corpus callosum (34)	144/147	0.0%	0.766	

Right anterior thalamic projections	18, 14, 10	-1.364	0.001125038	137	Right caudate nucleus (69) Right anterior thalamic projections (60)	144/147	0.0%	0.095
Left anterior thalamic projections	-14, 2, 14	-1.268	0.002198517	82	Left anterior thalamic projections (68) Left caudate nucleus (10)	139/147	0.0%	0.359

MDD, major depressive disorder; HC, healthy control; BA, Brodman areas; MNI, montreal neurological institute.

Table 3. Clusters showing differences between (rMDD vs. HC) versus (MDD vs. HC).

Local maximum region	Peak MNI coordinate (x, y, z)	SDM-Z	p	Cluster size / voxels	Breakdown (Number of voxels)	Heterogeneity I^2	Publish bias Egger's tests
rMDD > MDD							
Right inferior network, inferior longitudinal fasciculus	48, -14, -22	2.204	0.000211596	481	Right inferior network, inferior longitudinal fasciculus (167) Right middle temporal gyrus, BA 21 (137) Right inferior temporal gyrus, BA 20 (70) Right middle temporal gyrus, BA 20 (63) Right superior temporal gyrus, BA 21 (13)	0.0%	0.276
Right striatum	24, 14, 2	1.985	0.000485122	216	Right striatum (110) Right lenticular nucleus, putamen, BA 48 (77)	0.0%	0.684
Right anterior thalamic projections	18, 14, 10	1.925	0.000645101	130	Right anterior thalamic projections (79) Right caudate nucleus (47)	0.0%	0.206
Left inferior parietal, BA 40	-46, -46, 46	1.639	0.002606213	47	Left inferior parietal, BA 40 (47)	0.0%	0.860
Left median cingulate / paracingulate gyrus, BA 23	-4, -18, 42	1.593	0.003256509	34	Left median cingulate / paracingulate gyrus, BA 23 (29)	0.0%	0.664
rMDD < MDD							
Left cuneus cortex, BA 18	-8, -90, 24	-1.602	0.000928938	1054	Corpus callosum (341) Left cuneus cortex, BA 18 (264) Left superior occipital gyrus, BA 17 (187) Left calcarine fissure / surrounding cortex, BA 17 (150) Left middle occipital gyrus, BA 17 (78)	0.0%	0.639
Right middle temporal gyrus, BA 37	54, -62, 12	-1.763	0.000392199	220	Right middle temporal gyrus, BA 37 (163) Right middle temporal gyrus, BA 39 (43)	0.0%	0.854
Left superior frontal gyrus, medial, BA 10	-4, 58, 28	-1.427	0.002028227	118	Left superior frontal gyrus, medial, BA 10 (79)	0.0%	0.070

Right superior frontal gyrus, medial, BA 10

(14)

Corpus callosum (14)

MDD, major depressive disorder; rMDD, remitted major depressive disorder; HC, healthy control; BA, Brodman areas; MNI, montreal neurological institute.